SPONSOR
Hebei Medical University Fourth Hospital
Total Trials
5
Recruiting
5
Phases
Phase 2
Conditions studied: SCLC, Limited StageHepatocellular CarcinomaColorectal CancerEsophageal Squamous Cell Carcinoma (ESCC)Esophageal Neoplasms
Hebei Medical University Fourth Hospital is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including SCLC, Limited Stage, Hepatocellular Carcinoma, Colorectal Cancer, Esophageal Squamous Cell Carcinoma (ESCC).
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Hebei Medical University Fourth Hospital
How many clinical trials has Hebei Medical University Fourth Hospital sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by Hebei Medical University Fourth Hospital, of which 5 are actively recruiting participants. These trials cover conditions including SCLC, Limited Stage, Hepatocellular Carcinoma, Colorectal Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Hebei Medical University Fourth Hospital research focus on?
Hebei Medical University Fourth Hospital clinical trials span SCLC, Limited Stage, Hepatocellular Carcinoma, Colorectal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Neoplasms. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Hebei Medical University Fourth Hospital clinical trial?
To participate in a Hebei Medical University Fourth Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Hebei Medical University Fourth Hospital trials with current recruitment status updated daily.
Clinical Trials by Hebei Medical University Fourth Hospital
NCT06371482 Phase 2
Recruiting
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
SCLC, Limited Stage
NCT07179900 Phase 2
Recruiting
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Hepatocellular Carcinoma
NCT06184698 Phase 2
Recruiting
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
Colorectal Cancer
NCT07290010 Phase 2
Recruiting
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC)
NCT06646588 Phase 2
Recruiting
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma
Esophageal Neoplasms
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology